Clinical trial
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in…
NCT00130156 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00130156 |
|---|---|
| Title | Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension |
| Official title | Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Eisai Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | High Blood Pressure |
| Intervention type | Drug |
| Interventions | Bunazosin, Doxazosin, Valsartin |
| Enrollment | 93 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Aug 15, 2005 |
| Last update posted | May 14, 2013 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: